Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2024-01-08 00:00:00 ET · period of report 2024-01-04 · accession 0001209191-24-001143 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-01-08 | 2024-01-04 | ORMP | Sank Leonard | Dir | A - Grant | — | +39.3K | 98.0K | +67% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-04 | A | A | 30,000 | — | 88,696 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |
| 2 | Common | Common Stock | 2024-01-04 | A | A | 9,325 | — | 98,021 | D | — | — | (F2) Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 2,331 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |